The documented adverse-event profile of tirzepatide (brands Mounjaro and Zepbound) in the phase 3 registration trials is led by gastrointestinal reactions: nausea, diarrhoea, vomiting, constipation and reduced appetite. In most participants these were mild or moderate, transient and concentrated at the start of therapy and during dose escalation. Separately, the manufacturer's label records more serious warnings, a "boxed" warning about C-cell thyroid tumours (based on rodent data), a pancreatitis signal and a risk of gallbladder disease. Below is exactly what the SURMOUNT-1 and SURPASS-2 studies showed, with real frequencies, and which contraindications are documented.
This article is specifically about safety and tolerability. Dose-escalation schedules we cover separately, and the features of research-grade raw material in the tirzepatide monograph.
Why tirzepatide causes side effects at all
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Both incretin pathways affect gastric motility and slow gastric emptying, so the vast majority of adverse events are gastrointestinal in nature. This is exactly why tirzepatide side effects most often concern digestion rather than other systems.
It is important to distinguish the drug's status. Mounjaro (for type 2 diabetes) and Zepbound (for weight management) are medicines approved abroad, with their own labels and warnings. In the context of our catalogue we mean research-grade tirzepatide, a substance for laboratory and research use, not a finished prescription drug and not a recommendation for self-treatment.
Tirzepatide and Mounjaro: GI side effects from the study data
In the SURMOUNT-1 study (adults with obesity or overweight, 72 weeks) GI adverse events were the most frequent and dose-dependent. Frequencies for the 5 / 10 / 15 mg doses versus placebo:
| Adverse event | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 24.6% | 33.3% | 31.0% | 9.5% |
| Diarrhoea | 18.7% | 21.2% | 23.0% | 7.3% |
| Constipation | 16.8% | 17.1% | 11.7% | 5.8% |
| Vomiting | 8.3% | 10.7% | 12.2% | 1.7% |
| Discontinuation due to AEs | 4.3% | 7.1% | 6.2% | 2.6% |
Source: Jastreboff et al., NEJM 2022 (SURMOUNT-1).
In the SURPASS-2 study (adults with type 2 diabetes, tirzepatide versus semaglutide 1 mg, 40 weeks) the picture was similar, but frequencies were somewhat lower:
| Adverse event | 5 mg | 10 mg | 15 mg |
|---|---|---|---|
| Nausea | 17.4% | 19.2% | 22.1% |
| Diarrhoea | 13.2% | 16.4% | 13.8% |
| Vomiting | 5.7% | 8.5% | 9.8% |
Source: Frías et al., NEJM 2021 (SURPASS-2). For comparison, in the semaglutide group nausea was 17.9%, diarrhoea, 11.5%, vomiting, 8.3%, so the profile of the two drugs was broadly comparable.
The key pattern from both studies: most episodes of nausea, diarrhoea and vomiting were mild or moderate in severity, transient and occurred mainly during dose escalation rather than during maintenance therapy.
When adverse events are strongest
Both SURMOUNT-1 and SURPASS-2 showed that gastrointestinal reactions concentrate at the start and during dose escalation, and their frequency declines over time. That is why gradual titration is used in clinical practice. The share of participants who stopped therapy because of adverse events was 4.3–7.1% on active doses in SURMOUNT-1 versus 2.6% on placebo, so most continued treatment despite temporary discomfort.
This is important context for reading the query "mounjaro side effects": a high relative frequency of nausea does not mean a severe course, mild self-limiting episodes predominate.
Serious warnings and contraindications
Beyond gastrointestinal tolerability, the manufacturer's labels (Mounjaro / Zepbound) document a number of more serious safety signals. This is the core of the "mounjaro safety" question:
- C-cell thyroid tumours (boxed warning). In rodent studies tirzepatide caused C-cell thyroid tumours. Whether this applies to humans is unknown. Because of this the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2).
- Pancreatitis. A signal of acute pancreatitis was recorded in clinical studies. If suspected, the drug should be discontinued.
- Gallbladder disease. Gallstone disease (cholelithiasis) and cholecystitis were reported, in some cases, requiring cholecystectomy.
- Hypoglycaemia. The risk rises when combined with insulin or sulfonylureas; adjustment of concomitant therapy may be needed.
- Acute kidney injury. Severe vomiting and diarrhoea can lead to dehydration and worsening kidney function.
- Hypersensitivity reactions and injection-site reactions.
- Diabetic retinopathy, where present, requires monitoring.
- Interaction with oral contraceptives. Delayed gastric emptying can reduce their effectiveness, so the label recommends additional contraceptive measures during the start and dose increase.
This list is not exhaustive and does not replace the official label or a consultation with a qualified doctor.
Common versus rare: how not to confuse the categories
Reading the safety profile correctly means distinguishing two fundamentally different classes of event. The first, frequent but mostly mild and self-limiting gastrointestinal reactions (nausea, diarrhoea, vomiting, constipation): their frequencies in SURMOUNT-1 and SURPASS-2 run into tens of percent, yet most episodes are transient and concentrate around dose escalation. The second class, rare but potentially serious events (pancreatitis, gallbladder disease, acute kidney injury from dehydration), whose frequency is much lower but whose clinical weight is higher.
That is why assessing "mounjaro safety" does not reduce to a single nausea-frequency figure. The warning signs documented in the label that need attention include persistent severe abdominal pain radiating to the back (a pancreatitis signal), gallbladder symptoms, and a neck mass, hoarseness or difficulty swallowing (in the context of the thyroid warning). These scenarios are rare, but they define the serious part of the risk profile, while gastrointestinal tolerability describes its everyday part.
Data limitations and how to read them
A few caveats on interpreting these numbers. First, the frequencies from SURMOUNT-1 and SURPASS-2 come from different populations (obesity without diabetes versus type 2 diabetes), so they cannot be equated directly. Second, this is data from controlled trials with careful titration, and in real practice the profile may differ. Third, rare events (such as pancreatitis) are detected mainly in post-marketing surveillance rather than a single study.
For research use, the quality of the substance itself is separately critical: purity, identity and confirmation by a certificate of analysis (COA (certificate of analysis), Certificate of Analysis). That is on the research-grade tirzepatide page, and a full professional review of the compound is collected in the monograph.
The main points in brief
- The dominant adverse events of tirzepatide are gastrointestinal: nausea, diarrhoea, vomiting, constipation, reduced appetite.
- The highest frequencies, nausea up to 33.3% (SURMOUNT-1, 10 mg) and up to 22.1% (SURPASS-2, 15 mg); most episodes are mild/moderate and transient.
- Reactions intensify at the start and during dose escalation, then subside.
- Serious warnings: C-cell thyroid tumours (rodent data, boxed warning), pancreatitis, gallbladder disease; contraindications, a history of MTC or MEN 2.
